Hormonal
Dose de-escalation (tapering) or low-dose maintenance therapy may modestly limit the rate and magnitude of weight regain compared to abrupt cessation, but robust randomized evidence is currently lacking.
If you want to stop your incretin medication, talk to your doctor about tapering the dose or extending the time between injections rather than stopping abruptly. While this might help slow down weight regain, it is not a guaranteed solution, and you should expect some regain. Continuing at a lower dose is generally better than stopping completely.
dose tapering—reducing the dose or frequency of injections rather than abrupt cessation—may modestly limit the rate and magnitude of weight regain, though this approach is not yet supported by robust randomized controlled trial data.
Why this rating
Based on narrative reviews, case series, and modeling, not robust RCTs.
Source
Discontinuation of incretin-based therapies in obesity: the complexity of a breakup
A. Avogaro et al. · European Journal of Internal Medicine · 2026
DOI 10.1016/j.ejim.2026.106833
More from this paper
- Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.Strong
- Intensive lifestyle interventions (diet and exercise) alone are insufficient to prevent significant weight regain after discontinuation of incretin-based therapy, although they may modestly attenuate the rebound.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →